Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Saline breast implant research

This article was originally published in The Gray Sheet

Executive Summary

Potential autoimmune reaction to breast implants may be linked to the implants' silicone shell and not the contents of the prostheses, Henry Claman, MD, University of Colorado Health Sciences Center, Denver, reports to FDA. Both saline- and silicone gel-filled breast implants employ a silicone shell. In Jan. 26 comments on FDA's proposed call for saline-filled breast implants, Claman says his study results found that "there was no correlation between antinuclear antibody [ANA] positivity," which indicates autoimmune response, and the type of implant. "Thus, a positive ANA might be related to the silicone shell rather than the contents." Claman's research on over 100 patients recently was submitted to the Western Journal of Medicine.

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts